ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma

Estimates of cancer incidence and mortality in Europe in 2008

(2010) J. Ferlay et al.   EUROPEAN JOURNAL OF CANCER

Characterization of ST2 transgenic mice with resistance to IL-33

(2010) Hiromi Ohto-Ozaki et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

IL-33 promotes DC development in BM culture by triggering GM-CSF production

(2009) Nobuyasu Mayuzumi et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-γ production

(2009) Elvire Bourgeois et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

IL-33 receptor (T1/ST2) signalling is necessary to prevent the development of encephalitis in mice infected withToxoplasma gondii

(2009) Leigh A. Jones et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

IL-33 Amplifies the Polarization of Alternatively Activated Macrophages That Contribute to Airway Inflammation

(2009) M. Kurowska-Stolarska et al.   JOURNAL OF IMMUNOLOGY

Regulatory T cells and ST2 signaling control diabetes induction with multiple low doses of streptozotocin

(2009) Nemanja Zdravkovic et al.   MOLECULAR IMMUNOLOGY

Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33

(2008) T. Pecaric-Petkovic et al.   BLOOD

IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK Cells

(2008) M. D. Smithgall et al.   INTERNATIONAL IMMUNOLOGY